Funded Startups in Changping
Among the two disclosed rounds in Changping, Huaxia Yingtai’s $29M (Series C, 2026-07-06) is the largest disclosed amount and clearly dwarfs the next-large…
Among the two disclosed rounds in Changping, Huaxia Yingtai’s $29M (Series C, 2026-07-06) is the largest disclosed amount and clearly dwarfs the next-largest disclosed round at $14M for Enze Kangtai (Series B, 2025-11-03). The other three entries in the page window list undisclosed amounts, so disclosed deal size is concentrated in just two figures rather than spreading across multiple disclosed rounds.
The only consistently repeating geography is Changping (all 5 entries), with deal dates spanning 2025-09-20 (Chinagene Tech) to 2026-07-20 (Yuequan Bionics). Biotech appears as a recurring sector thread: Huaxia Yingtai (biopharma/biotechnology, 2026-07-06), Enze Kangtai (biotechnology, 2025-11-03), Veminsyn (biotechnology, 2025-10-01), and Chinagene Tech (healthcare, 2025-09-20), while stages are skewed toward Series B/C among the disclosed rows.
Most recent rounds
5 shownRelated listings
Frequently asked
What’s the largest disclosed round in Changping on this page, and how does it compare to the other disclosed amount?
Huaxia Yingtai’s disclosed $29M (Series C, 2026-07-06) is the top disclosed figure and significantly larger than Enze Kangtai’s disclosed $14M (Series B, 2025-11-03). The remaining three entries—Yuequan Bionics (2026-07-20), Veminsyn (2025-10-01), and Chinagene Tech (2025-09-20)—are listed as undisclosed.
Is Changping over-represented in this listing, or do these companies span multiple cities?
All five rows are based in Changping, China (including Yuequan Bionics on 2026-07-20 and Chinagene Tech on 2025-09-20). There are no alternate city names in the shown data.
Which rows fall in the most recent 90-day window from the latest listed round date?
The latest round date shown is 2026-07-20 (Yuequan Bionics). Within roughly the prior 90 days, Huaxia Yingtai (2026-07-06, Series C) and Yuequan Bionics (2026-07-20, Series A) are the only two entries in that window.
How does the sector mix cluster, and is there a biotech/health tilt?
Biotech-related work dominates the visible sectors: Huaxia Yingtai (biopharma/biotechnology, 2026-07-06), Enze Kangtai (biotechnology, 2025-11-03), and Veminsyn (biotechnology, 2025-10-01) plus Chinagene Tech (healthcare, 2025-09-20). Only Yuequan Bionics adds a more manufacturing/robotics/service-industry framing (2026-07-20) alongside its Changping location.
Are there stage patterns or outliers among the disclosed rounds?
Among disclosed amounts, the page shows a Series C at $29M (Huaxia Yingtai, 2026-07-06) and a Series B at $14M (Enze Kangtai, 2025-11-03). The main “outlier” in disclosed size is Huaxia Yingtai at $29M, while the largest other disclosed figure is the $14M Series B, and three additional Series B/Series A entries remain undisclosed.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.